GlassScriptPhysician profile
Rahul Thampi
NPI 1194109041
$4,908.42
in general payments reported to CMS, 2019-2025
30 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.92 · 2020: $262 · 2021: $121 · 2022: $162 · 2023: $1,440 · 2024: $1,445 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274 · Education: $30.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,273.96 |
| Education | $30.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $950.77 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $629.75 | 2021-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.56 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $251.81 | 2021-2025 | Omnipod |
| Medtronic, INC. | $239.24 | 2023-2025 | Minimed 780g, Inceptiv |
| Novartis Pharmaceuticals Corporation | $234.22 | 2023-2024 | |
| Corcept Therapeutics | $225.73 | 2021-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $185.22 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Beta Bionics, INC. | $178.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $177.37 | 2024-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $152.43 | 2022-2024 | |
| Abbott Laboratories | $152.25 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $138.37 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $137.43 | 2022-2025 | |
| Horizon Therapeutics Plc | $123.81 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87.39 | 2023-2025 | Synthroid |
| Alexion Pharmaceuticals, INC. | $82.81 | 2022-2024 | Strensiq |
| Ascendis Pharma Endocrinology INC | $81.58 | 2023-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $68.96 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $67.86 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $58.92 | 2019 | |
| Averitas Pharma INC. | $49.70 | 2025 | Qutenza |
| Recordati_rare_diseases_inc. | $47.35 | 2024 | Isturisa, Signifor Lar |
| Ascensia Diabetes Care US INC. | $45.82 | 2023 | |
| Esperion Therapeutics, INC. | $44.81 | 2025 | Nexletol |
| Sequel Med Tech, LLC | $38.43 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $31.93 | 2023 | Imcivree |
| Madrigal Pharmaceuticals | $24.27 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $23.38 | 2025 | |
| Amneal Pharmaceuticals LLC | $18.04 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Thampi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.